Clinical Trials Browser

Phase 2 × Hematologic Neoplasms × HuMax-IL8 × Clear all

NCT04347226 2025-05-22

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

Phase 2 Terminated

43 enrolled 14 charts

Other hematologic neoplasm

COVID-19, Coronavirus Infections, Hematologic Neoplasms